334 related articles for article (PubMed ID: 12752754)
1. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases.
Rapoport AM; Bigal ME; Volcy M; Sheftell FD; Feleppa M; Tepper SJ
Headache; 2003 May; 43(5):482-9. PubMed ID: 12752754
[TBL] [Abstract][Full Text] [Related]
2. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study.
Sheftell FD; Rapoport AM; Tepper SJ; Bigal ME
Headache; 2005; 45(10):1400-6. PubMed ID: 16324173
[TBL] [Abstract][Full Text] [Related]
3. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.
Newman L; Mannix LK; Landy S; Silberstein S; Lipton RB; Putnam DG; Watson C; Jöbsis M; Batenhorst A; O'Quinn S
Headache; 2001 Mar; 41(3):248-56. PubMed ID: 11264684
[TBL] [Abstract][Full Text] [Related]
4. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Göbel H; Winter P; Boswell D; Crisp A; Becker W; Hauge T; Mihout B; Niewold J; Tørring J
Clin Ther; 2000 Aug; 22(8):981-9. PubMed ID: 10972634
[TBL] [Abstract][Full Text] [Related]
5. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
Klassen A; Elkind A; Asgharnejad M; Webster C; Laurenza A
Headache; 1997; 37(10):640-5. PubMed ID: 9439085
[TBL] [Abstract][Full Text] [Related]
6. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.
Brandes JL; Smith T; Diamond M; Ames MH
Headache; 2007 Jun; 47(6):886-94. PubMed ID: 17578540
[TBL] [Abstract][Full Text] [Related]
7. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.
Sheftell F; O'Quinn S; Watson C; Pait D; Winter P
Headache; 2000 Feb; 40(2):103-10. PubMed ID: 10759909
[TBL] [Abstract][Full Text] [Related]
8. Naratriptan in the short-term prophylaxis of pure menstrual migraine.
Moschiano F; Allais G; Grazzi L; Usai S; Benedetto C; D'Amico D; Roncolato M; Bussone G
Neurol Sci; 2005 May; 26 Suppl 2():s162-6. PubMed ID: 15926020
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group.
Heywood J; Bomhof MA; Pradalier A; Thaventhiran L; Winter P; Hassani H
Cephalalgia; 2000 Jun; 20(5):470-4. PubMed ID: 11037743
[TBL] [Abstract][Full Text] [Related]
11. Managing intractable migraine with naratriptan.
Gallagher RM; Mueller L
Headache; 2003 Oct; 43(9):991-3. PubMed ID: 14511276
[TBL] [Abstract][Full Text] [Related]
12. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
Mathew NT; Asgharnejad M; Peykamian M; Laurenza A
Neurology; 1997 Dec; 49(6):1485-90. PubMed ID: 9409334
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
Garcia-Ramos G; MacGregor EA; Hilliard B; Bordini CA; Leston J; Hettiarachchi J
Cephalalgia; 2003 Nov; 23(9):869-76. PubMed ID: 14616928
[TBL] [Abstract][Full Text] [Related]
14. Naratriptan: an alternative for migraine.
Dulli DA
Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
[TBL] [Abstract][Full Text] [Related]
15. Prevention of migraine during prodrome with naratriptan.
Luciani R; Carter D; Mannix L; Hemphill M; Diamond M; Cady R
Cephalalgia; 2000 Mar; 20(2):122-6. PubMed ID: 10961768
[TBL] [Abstract][Full Text] [Related]
16. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Ashcroft DM; Millson D
Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):73-82. PubMed ID: 14998068
[TBL] [Abstract][Full Text] [Related]
17. Out-patient detoxification in chronic migraine: comparison of strategies.
Krymchantowski AV; Moreira PF
Cephalalgia; 2003 Dec; 23(10):982-93. PubMed ID: 14984232
[TBL] [Abstract][Full Text] [Related]
18. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.
Bigal ME; Rapoport AM; Sheftell FD; Tepper SJ; Lipton RB
Cephalalgia; 2004 Jun; 24(6):483-90. PubMed ID: 15154858
[TBL] [Abstract][Full Text] [Related]
19. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study.
Stronks DL; Tulen JH; Bussmann HB; Mulder LJ; Passchier J
Headache; 2003 Sep; 43(8):845-52. PubMed ID: 12940805
[TBL] [Abstract][Full Text] [Related]
20. Re: "Naratriptan in the prophylaxis of transformed migraine" (Sheftell FD Rapoport AM, Coddon DR. Headache.1999,39:506-510).
Warner JS
Headache; 2000 Mar; 40(3):252. PubMed ID: 10970177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
